Camizestrant
ER-Positive HER2-Negative Breast Cancer
AstraZenecaSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the ER-Positive HER2-Negative Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Arimidex AstraZeneca | Phase 3 | B |
Abemaciclib AstraZeneca | Phase 3 | B |
LEUPROLIDE AstraZeneca | Phase 3 | B |
Zoladex AstraZeneca | Phase 3 | B |
FULVESTRANT AstraZeneca | Phase 3 | B |
Ribociclib AstraZeneca | Phase 3 | B |
Letrozole AstraZeneca | Phase 3 | B |
Palbociclib AstraZeneca | Phase 3 | B |
Same molecule, other indications
Camizestrant is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →